FDA grants GlycoMimetics rare paediatric disease designation for rivipansel for treatment of sickle cell disease

This article was originally published here

“The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during childhood with life-long implications. With this designation, the

The post FDA grants GlycoMimetics rare paediatric disease designation for rivipansel for treatment of sickle cell disease appeared first on Pharmaceutical Business review.